Tirofiban potentiates agonist-induced platelet activation and degranulation, despite effectively inhibiting aggregation

We aimed to investigate the effects of integrin αIIbβ3 inhibitor tirofiban on hallmarks of platelet activation, degranulation, and aggregation during its use to analyze activated but non-complexed platelets via flow cytometry. To do so, we used washed platelets from healthy human donors. We combined...

Full description

Saved in:
Bibliographic Details
Published in:Platelets (Edinburgh) Vol. 33; no. 8; pp. 1192 - 1198
Main Authors: Aguiar Bucsai, Martina, Idel, Christian, Wollenberg, Barbara, Mannhalter, Christine, Verschoor, Admar
Format: Journal Article
Language:English
Published: England Taylor & Francis 17.11.2022
Taylor & Francis Group
Subjects:
platelet activation
platelet aggregation
platelet degranulation
platelet inhibition
tirofiban
platelet inhibition
platelet degranulation
tirofiban
platelet activation
platelet aggregation
ISSN:0953-7104, 1369-1635, 1369-1635
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to investigate the effects of integrin αIIbβ3 inhibitor tirofiban on hallmarks of platelet activation, degranulation, and aggregation during its use to analyze activated but non-complexed platelets via flow cytometry. To do so, we used washed platelets from healthy human donors. We combined aggregometry, an assay of platelet functionality, with flow cytometry and ELISA to detect and correlate, respectively, platelet aggregation, activation, and granule release. While tirofiban effectively inhibited agonist-induced platelet aggregation (thrombin receptor-activating peptide 6 (TRAP), convulxin (CVX), U46619 and IV.3), the surface expression of P-selectin and CD63 and granule release of RANTES were significantly increased, indicating that tirofiban enhances degranulation, uncoupled from aggregation. The results show that tirofiban alters the activation phenotype of platelets, something that should be considered when using tirofiban to enable flow cytometric analysis of activated but unaggregated platelet suspensions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0953-7104
1369-1635
1369-1635
DOI:10.1080/09537104.2022.2078489